Talk to a specialist nurse

0808 800 0035
Icon
Icon
Icon

Atypical thigh bone fractures and drug treatments for osteoporosis 

Atypical thigh bone fractures are a rare side effect linked with some osteoporosis drug treatments. The drug treatments are alendronate, ibandronate, risedronate, zoledronate, denosumab and romosozumab. Atypical thigh bone fractures are linked with taking these treatments for many years. They don't happen often. You might hear these breaks described as atypical femoral fractures. 

Atypical means 'unusual'. Atypical thigh bone fractures are unusual because they are different from fractures caused by osteoporosis. Most fractures caused by osteoporosis are in the wrists, hips and spine. But atypical thigh bone fractures happen in the large, main bone in your thigh (femur). The bone breaks without you falling over. 

The benefits of taking a drug treatment for osteoporosis are likely to far outweigh any possible risks of getting an atypical thigh bone fracture. 

Download our fact sheet

Atypical thigh bone fractures

What are atypical thigh bone fractures? 

Atypical thigh bone fractures are breaks that occur along the main part of the thigh bone. They can happen in one or both thighs.

Atypical thigh bone fractures are rare. They can happen in people taking some drug treatments for osteoporosis.

Why are atypical thigh bone fractures unusual? 

Atypical thigh bone fractures are unusual. This is because they are different from fractures caused by osteoporosis.

Here are some of the main differences.

Fractures caused by osteoporosis:

  • usually happen after a fall, except for spinal fractures
  • are most common in the wrists, hips and spine.

Atypical thigh bone fractures:

  • are often drug-related
  • happen in one or both thighs.

 

What drug treatments are linked with atypical thigh bone fractures and how do they increase risk?

Bisphosphonates are a type of medication linked with atypical thigh bone fractures. This group of drugs includes:

  • alendronate (also known as alendronic acid, Fosamax®, Binosto® and Fosavance®)
  • ibandronate (also known as ibandronic acid and Bonviva®)
  • risedronate (also known as Actonel®)
  • zoledronate (also known as zoledronic acid and Aclasta®)

Denosumab (also known as Prolia®) and romosozumab (also known as Evenity®) are also linked with atypical thigh bone fractures.

Research has shown that having these types of treatments for a long time increases the risk of atypical thigh bone fractures. But research has not proven why these treatments increase risk over time.

What do the drug treatments do and how do they work? 

Bones are made up of living tissue. The inside of our bones is constantly being broken down and rebuilt by specialist bone cells. As long as this process is in balance, your bones should stay healthy and strong.

But if the process becomes out of balance, our bodies start to break down more bone than we build. This can cause the bones to become weaker and more likely to break easily.

Many of the osteoporosis drugs work by slowing down the cells that break down bone. This helps to restore the balance and make your bones stronger.

Some experts think taking these medications for many years might slow down the cells that break down bone for too long. This could increase the risk of atypical thigh bone fractures.

 

How common are atypical thigh bone fractures?

Atypical thigh bone fractures are rare. We don't know exactly how many people get them because there isn't much information available. 

Some research has shown if 1,000 people were taking drug treatments linked to atypical thigh bone fractures, less than 1 person would have an atypical thigh bone fracture. The other 999 out of 1,000 people would not have an atypical thigh bone fracture.

The risk of having an atypical thigh bone fracture is low. If you’ve been offered a drug treatment for osteoporosis, this means your risk of breaking a bone is high enough that your bones would benefit from a drug treatment. For you, the benefits outweigh any possible risks. In other words, your risk of atypical thigh bone fractures is smaller than your risk of breaking a bone if you don’t have treatment. 

 

What can I do to reduce my risk? 

Some research shows that stopping treatment for a while may reduce your risk of atypical thigh bone fractures.

If you’ve been taking a bisphosphonate treatment for about five years, you may be advised to pause your treatment. This will usually be for one to three years. It’s called a 'treatment pause' or 'drug holiday'.

Bisphosphonates keep helping your bones for a while after you stop taking them.

If you’re at a high risk of breaking a bone, your doctor may advise you to stay on your drug treatment without pausing.

You can only pause treatment if you’re taking a bisphosphonate.

Denosumab and romosozumab don’t continue helping your bones for a while after you stop taking them. A treatment pause won’t be an option for this reason.

It is especially important you don’t pause denosumab. Some people have had several spinal fractures in the following months after they’ve stopped denosumab. This is known as the ‘rebound effect’. To stop the effect, you’ll need to take another drug treatment.

It’s important to take your drug treatment correctly. Make sure you read – and understand – the leaflet that comes with your treatment. If you don’t have a copy, ask your doctor or pharmacist for one.

 

How do I know if I have an atypical thigh bone fracture? 

The main symptom of an atypical thigh bone fracture is a new, unexplained pain in your thigh or groin area while taking an osteoporosis drug treatment. If you have this type of pain, speak to a doctor.

If your pain is severe, see a doctor in a few days. If you have less severe pain, speak to a doctor within a few weeks.

 

What happens if I have an atypical thigh bone fracture? 

If your doctor thinks you might have an atypical thigh bone fracture, they will refer you for an x-ray. They may also offer you crutches. The crutches will limit how much weight you put on your leg when walking or standing.

If your x-ray shows any unusual changes or fine cracks in your thigh bones, this may mean you have the start of an atypical thigh bone fracture. A specialist doctor may suggest an operation before your bone fractures fully or gets worse.

If your x-ray shows you have an atypical thigh bone fracture, your doctor will usually advise you:

  • stop taking the drug treatment
  • have an operation to fix the bone.

If you’re on denosumab, you must get advice from a hospital specialist before stopping treatment.

People who have an atypical thigh bone fracture in one leg might be more likely to have a fracture in the other leg. Stopping treatment may help prevent another fracture from happening. You are often offered an x-ray of your other thigh to make sure it’s not affected too.

If you have an atypical thigh bone fracture, you’ll likely need an operation to fix the bone. It could take about four to six months to heal after an operation, but this varies from person to person.

You should be offered crutches and referred to a physiotherapist. They can help you to stand and walk after your operation.

In a few cases, fractures don’t heal properly after an operation. If this happens, you may need to have another operation to try and fix the bone again.

 

What can I do if I'm worried about atypical thigh bone fractures?

Some people might be concerned about the possible health risks of taking a drug treatment.

No-one can make you have treatment if you don’t want it. But do take time to understand the benefits and possible risks – both of taking the drug treatment, and of not taking it.

Take care when visiting online forums or chat groups on social media. Reading about other people’s experiences can be helpful. But you may not always see a balance of views online. People are more likely to seek support for bad experiences than good ones. This can make it seem that everyone has problems with drug treatments. In reality, most people have no side effects at all.

There is a low risk of having atypical thigh bone fractures when taking bisphosphonates, denosumab and romosozumab. But atypical thigh bone fractures are rare.

If you do feel worried, before or during your treatment, talk to your doctor or pharmacist, or contact our specialist Helpline nurses.

There may be another drug treatment you feel is more suitable for you.

 

The Medicines and Healthcare products Regulatory Agency (MHRA) makes sure drugs work well and are safe. You can report medication side effects through the MHRA's 'Yellow Card Scheme'. This may be particularly helpful if you've experienced a rare side effect, such as an atypical thigh bone fracture. 

 

Content reviewed: January 2024

  • Aspenberg P. Denosumab and atypical femoral fractures. Acta Orthop. 2014;85(1):1. doi:10.3109/17453674.2013.859423
  • Bisphosphonates: atypical femoral fractures - GOV.UK. Accessed August 11, 2023. https://www.gov.uk/drug-safety-update/bisphosphonates-atypical-femoral-fractures 
  • Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. New England Journal of Medicine. 2020;383(8):743-753. doi:10.1056/NEJMOA1916525/SUPPL_FILE/NEJMOA1916525_DISCLOSURES.PDF
  • Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. Endocr Rev. 2019;40(2):333-368. doi:10.1210/ER.2018-00001
  • Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544-2550. doi:10.1002/JBMR.1719
  • Khan AA, Kaiser S. Atypical femoral fracture. CMAJ : Canadian Medical Association Journal. 2017;189(14):E542. doi:10.1503/CMAJ.160450
  • Khow KSF, Shibu P, Yu SCY, Chehade MJ, Visvanathan R. Epidemiology and postoperative outcomes of atypical femoral fractures in older adults: A systematic review. Journal of Nutrition, Health and Aging. 2017;21(1):83-91. doi:10.1007/S12603-015-0652-3/METRICS
  • Overview | Osteoporosis: assessing the risk of fragility fracture | Guidance | NICE.
  • Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728-1737. doi:10.1056/NEJMOA1010650
  • Tsuchiya K, Okano I, Shiose K, et al. Atypical femoral fracture mimicking lumbar radiculopathy in two patients taking bisphosphonate long-term: A case report. BMC Musculoskelet Disord. 2022;23(1):1-5. doi:10.1186/S12891-022-05990-7/FIGURES/4
  • van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. J Clin Endocrinol Metab. 2020;105(5). doi:10.1210/CLINEM/DGZ295

Help our specialist nurses continue to support those in need


Image